HPV ve erkek cinsel sağlığı
Human papilloma virüs (HPV), dünyada en sık görülen cinsel yol ile bulaşan enfeksiyon (CYBE) etkenidir. HPV, genital bölgede kondiloma aküminatum adı verilen siğillere, prekanseröz ve kanseröz lezyonlara yol açabilir. Onkojenik bir virüs olan HPV’nin serviks kanseri ile birlikteliğinin %100 olması ve daha önceki prevalans çalışmalarının genellikle kadınlar üzerinde yapılmış olması erkeklerdeki HPV enfeksiyonunu geri planda bırakmıştır. Son yıllarda erkeklerin dâhil edildiği prevalans çalışmalarının artması, penil intraepitelyal neoplazi (PIN)’li hastalarla %70–100 ve penis kanseriyle %50 oranında olan birlikteliği, penil uretral meatusta ve nadiren uretrada görülmesi, birkaç çalışmada prostat kanseri ile ilişkilendirilmesi ve erkek infertilitesine yol açması sebebiyle erkek cinsel sağlığı açısından bilinmesi ve önem verilmesi gereken bir virüstür. Bu derleme erkeklerde görülen HPV enfeksiyonlarının güncel tanı, tedavi ve korunma yollarını değerlendirmeyi amaçlamıştır.
HPV and men’s sexual health
Human papilloma virus (HPV) is the most common sexually transmitted infection (STI) agent in the world. HPV can cause genital warts called condyloma acuminatum as well as precancerous and cancerous lesions. The 100% association of HPV, an oncogenic virus, with cervical cancer, and the fact that previous prevalence studies were generally conducted on women, left HPV infection in men in the background. Because of the increase in prevalence studies including men and the association of patients with penile intraepithelial neoplasia (PIN) at a rate of 70–100% and those with penile cancer at a rate of 50%; in addition since it is seen in the penile urethral meatus and rarely in the urethra and associated with prostate cancer in several studies; leading to male infertility, it is a virus that should be known and given importance in terms of male sexual health. This review aimed to evaluate the current diagnosis, treatment and prevention methods of HPV infections in men.
___
- 1. Heidegger I, Borena W, Pichler R. The role of human papilloma virus in urological malignancies. Anticancer Res. 2015;35:2513–9. https://pubmed.ncbi.nlm.nih.gov/25964524/
- 2. Quinlan JD. Human papillomavirus: screening, testing, and prevention. Am Fam Physician. 2021;104:152–9. https://pubmed. ncbi.nlm.nih.gov/34383440/
- 3. Pandhi D, Sonthalia S. Human papilloma virus vaccines: current scenario. Indian J Sex Transm Dis. 2011;32:75–85. [CrossRef]
- 4. McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER, Paulose-Ram R. Prevalence of HPV in adults aged 18–69: United States, 2011–2014. NCHS Data Brief. 2017;(280):1–8. https:// pubmed.ncbi.nlm.nih.gov/28463105/
- 5. Rodríguez-Álvarez MI, Gómez-Urquiza JL, Husein-El Ahmed H, Albendín-García L, Gómez-Salgado J, Cañadas-De la Fuente GA. Prevalence and risk factors of human papillomavirus in male patients: a systematic review and meta-analysis. Int J Environ Res Public Health. 2018;15:2210. [CrossRef]
- 6. Nielson CM, Flores R, Harris RB, Abrahamsen M, Papenfuss MR, Dunne EF, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev. 2007;16:1107–14. [CrossRef]
- 7. Moreno-Sepulveda J, Rajmil O. Seminal human papillomavirus infection and reproduction: a systematic review and meta-analysis. Andrology 2021;9:478–502. [CrossRef]
- 8. Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18:240–54. [CrossRef]
- 9. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68:362–72. [CrossRef]
- 10. Feller L, Khammissa RA, Wood NH, Lemmer J. Epithelial maturation and molecular biology of oral HPV. Infect Agents Cancer. 2009;4:16. [CrossRef]
- 11. Best SR, Niparko KJ, Pai SI. Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers. Otolaryngol Clin North Am. 2012;45:807–22. [CrossRef]
- 12. Luria L, Cardoza-Favarato G. Human Papillomavirus. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan 24.
- 13. Cobo F. Human Papillomavirus Infections: From the Laboratory to Clinical Practice. 1st ed. Elsevier: Woodhead Publishing Series in Biomedicine; 2012.
- 14. Fernandes JV, Fernandes TAAM. Human papillomavirus: biology and pathogenesis. In: Broeck DV, editor. Human Papillomavirus and Related Diseases - From Bench to Bedside - A Clinical Perspective. Croatia: InTech; 2012. (360 p). http://icrh.org/sites/ default/files/Human%20papillomavirus%20and%20related%20 diseases%2C%20from%20bench%20to%20bedside%20-%20 a%20clinical%20perspective.pdf
- 15. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609–16. [CrossRef]
- 16. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664–70. [CrossRef]
- 17. Anic GM, Giuliano AR. Genital HPV infection and related lesions in men. Prev Med. 2011;53 Suppl 1:S36–41. [CrossRef]
- 18. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182–92. [CrossRef]
- 19. Lipke MM. An armamentarium of wart treatments. Clin Med Res. 2006;4:273–93. [CrossRef]
- 20. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccin Immunother. 2019;15:146–55. [CrossRef]
- 21. Stratton KL, Culkin DJ. A contemporary review of HPV and penile cancer. Oncology (Williston Park). 2016;30:245–9. https:// pubmed.ncbi.nlm.nih.gov/26984219/
- 22. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1–187. [CrossRef]
- 23. Balaji R, MacCosham A, Williams K, El-Zein M, Franco EL. Directionality of genital human papillomavirus infection transmission within heterosexual couples: a systematic review and meta-analysis. J Infect Dis. 2020;222:1928–37. [CrossRef]
- 24. Brewer NT, Calo WA. HPV transmission in adolescent men who have sex with men. Lancet Infect Dis. 2015;15:8–9. [CrossRef]
- 25. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–9. [CrossRef]
- 26. Li S, Ni XB, Xu C, Wang XH, Zhang C, Zeng XT. Oral sex and risk of oral cancer: a meta-analysis of observational studies. J Evid Based Med. 2015;8:126–33. [CrossRef]
- 27. Vogt SL, Gravitt PE, Martinson NA, Hoffmann J, D’Souza G. Concordant oral-genital HPV infection in South Africa couples: evidence for transmission. Front Oncol. 2013;3:303. [CrossRef]
- 28. Petca A, Borislavschi A, Zvanca ME, Petca RC, Sandru F, Dumitrascu MC. Non-sexual HPV transmission and role of vaccination for a better future (Review). Exp Ther Med. 2020;20:186. [CrossRef]
- 29. Leslie SW, Sajjad H, Kumar S. Genital Warts. 2022 May 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
- 30. Malagón T, Louvanto K, Wissing M, Burchell AN, Tellier PP, ElZein M, et al. Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study. Lancet Infect Dis 2019;19:317–26. [CrossRef]
- 31. Freitas AC, Mariz FC, Silva MA, Jesus AL. Human papillomavirus vertical transmission: review of current data. Clin Infect Dis. 2013;56:1451–6. [CrossRef]
- 32. Gallay C, Miranda E, Schaefer S, Catarino R, Jacot-Guillarmod M, Menoud PA, et al. Human papillomavirus (HPV) contamination of gynaecological equipment. Sex Transm Infect. 2016;92:19–23. [CrossRef]
- 33. Casalegno JS, Le Bail Carval K, Eibach D, Valdeyron ML, Lamblin G, Jacquemoud H, et al. High risk HPV contamination of endocavity vaginal ultrasound probes: an underestimated route of nosocomial infection? PLoS One. 2012;7:e48137. [CrossRef]
- 34. Ferenczy A, Bergeron C, Richart RM. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. Obstet Gynecol. 1989;74:950–4. https://pubmed.ncbi.nlm.nih.gov/2555753/
- 35. Liu Z, Rashid T, Nyitray AG. Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration. Sex Health. 2016;13:10–21. [CrossRef]
- 36. Houlihan CF, Baisley K, Bravo IG, Pavón MA, Changalucha J, Kapiga S, et al. Human papillomavirus DNA detected in fingertip, oral and bathroom samples from unvaccinated adolescent girls in Tanzania. Sex Transm Infect. 2019;95:374–9. [CrossRef]
- 37. Palma S, Gnambs T, Crevenna R, Jordakieva G. Airborne human papillomavirus (HPV) transmission risk during ablation procedures: a systematic review and meta-analysis. Environ Res 2021;192:110437. [CrossRef]
- 38. Fox-Lewis A, Allum C, Vokes D, Roberts S. Human papillomavirus and surgical smoke: a systematic review. Occup Environ Med. 2020;77:809–17. [CrossRef]
- 39. Lacey CJN. Genital warts and mucosal papilloma virus disease. Medicine. 2014;42:349–53. [CrossRef]
- 40. Leung AK, Barankin B, Leong KF, Hon KL. Penile warts: an update on their evaluation and management. Drugs Context. 2018;7:212563. [CrossRef]
- 41. O’Mahony C, Gomberg M, Skerlev M, Alraddadi A, de Las HerasAlonso ME, Majewski S, et al. Position statement for the diagnosis and management of anogenital warts. J Eur Acad Dermatol Venereol. 2019;33:1006–19. [CrossRef]
- 42. Giuliano AR, Nielson CM, Flores R, Dunne EF, Abrahamsen M, Papenfuss MR, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis. 2007;196:1146–52. [CrossRef]
- 43. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J. 2006;12:5. [CrossRef]
- 44. Giuliano AR, Sirak B, Abrahamsen M, Silva RJC, Baggio ML, Galan L, et al. Genital wart recurrence among men residing in Brazil, Mexico, and the United States. J Infect Dis. 2019;219:703– 10. [CrossRef]
- 45. Gutierrez P, Garza J, Gandhi K, Voice A, Stout E, Ventolini G. Carbon dioxide (CO2) laser ablation treatment of a periurethral genital wart: A case report. Case Rep Womens Health. 2020;27:e00226. [CrossRef]
- 46. Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a metaanalysis. Sex Transm Dis. 2008;35:346–51. [CrossRef]
- 47. Long FQ, Zhao LS, Qian YH. Vitiligo or vitiligo-like hypopigmentation associated with imiquimod treatment of condyloma acuminatum: not a casual event. Chin Med J (Engl). 2017;130:503–4. [CrossRef]
- 48. Tzellos TG, Sardeli C, Lallas A, Papazisis G, Chourdakis M, Kouvelas D. Efficacy, safety and tolerability of green tea catechins in the treatment of external anogenital warts: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2011;25:345– 53. [CrossRef]
- 49. Hara Y. Tea catechins and their applications as supplements and pharmaceutics. Pharmacol Res. 2011;64:100–4. [CrossRef]
- 50. Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2020;34:1644–53. [CrossRef]
- 51. Hoyme UB, Hagedorn M, Schindler A-E, Schneede P, Hopfenmüller W, Schorn K et al. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment. Infect Dis Obstet Gynecol. 2002;10:79–88. [CrossRef]
- 52. Del Zingaro M, Cochetti G, Zucchi A, Paladini A, Rossi De Vermandois JA, Ciarletti S, et al. Holmium: YAG laser for the treatment of genital and urethral warts: multicentre prospective evaluation of safety and efficacy. J Lasers Med Sci. 2021;12:e34. [CrossRef]
- 53. Iranmanesh B, Khalili M, Zartab H, Amiri R, Aflatoonian M. Laser therapy in cutaneous and genital warts: a review article. Dermatol Ther. 2021;34:e14671. [CrossRef]
- 54. de Lima MM Jr, de Lima MM, Granja F. Treatment of genital lesions with diode laser vaporization. BMC Urol. 2015;15:39. [CrossRef]
- 55. Salman S, Ahmed MS, Ibrahim AM, Mattar OM, El-Shirbiny H, Sarsik S, et al. Intralesional immunotherapy for the treatment of warts: A network meta-analysis. J Am Acad Dermatol. 2019;80:922–30.e4. [CrossRef]
- 56. Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M, et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis. 2001;33:597–602. [CrossRef]
- 57. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician. 2004;70:2335–42. https://pubmed.ncbi.nlm.nih. gov/15617297/
- 58. Jeje EA, Ogunjimi MA, Alabi TO, Awolola NA, Ojewola RW. Condyloma acuminata of the bladder in benign prostatic obstruction: Case report and review of literature. Niger Postgrad Med J. 2015;22:189–93. [CrossRef]
- 59. Olsen S, Marcussen N, Jensen KM, Lindeberg H. Urethral condylomata, due to human papilloma virus (HPV) type 6/11, associated with transitional cell tumors in the bladder and ureter. A case report. Scand J Urol Nephrol Suppl. 1995;172:51–5. https:// pubmed.ncbi.nlm.nih.gov/8578257/
- 60. Amato NA, Moretti FS, Boscia FM, Mele F. Urinary bladder, urethral and renal condylomata, due to human papilloma virus (HPV) type 11 associated with transitional cell tumors in bladder, ureter and kidney: a case report. Minerva Ginecol. 2008;60:264–5. https://pubmed.ncbi.nlm.nih.gov/18547990/
- 61. Murray AJ, Bivalacqua TJ, Sopko NA. Innumerable condyloma acuminatum tumors of the bladder. Urol Case Rep. 2017;12:76–7. [CrossRef]
- 62. Samarska IV, Epstein JI. Condyloma acuminatum of urinary bladder: relation to squamous cell carcinoma. Am J Surg Pathol. 2019;43:1547–53. [CrossRef]
- 63. Ebrahimi A, Moradi MR, Rezaei M, Kavoussi H, Madani H, Mohammadamini K, et al. Comparison of the risk factors and HPV types in males with anogenital warts with and without involvement of the urethral meatus in western Iran. Acta Dermatovenerol Alp Pannonica Adriat. 2017;26:55–8. [CrossRef]
- 64. Sumino Y, Mimata H, Nomura Y. Urethral condyloma acuminata following urethral instrumentation in an elderly man. Int J Urol. 2004;11:928–30. [CrossRef]
- 65. Walasek A, Myers FA, Sullivan JF, Emeruwa C, Shields JM, Winer AG. Pan-urethral condylomata acuminata in an immunocompromised patient. Urology. 2019;132:18–21. [CrossRef]
- 66. Fralick RA, Malek RS, Goellner JR, Hyland KM. Urethroscopy and urethral cytology in men with external genital condyloma. Urology. 1994;43:361–4. [CrossRef]
- 67. Zayko MO, Velilla RE, Shurbaji MS condyloma acuminata presenting as isolated papillary lesions in the prostatic urethra. Am J Case Rep. 2018;19:1522–5. [CrossRef]
- 68. Kaplinsky RS, Pranikoff K, Chasan S, DeBerry JL. Indications for urethroscopy in male patients with penile condylomata. J Urol. 1995;153:1120–1. [CrossRef]
- 69. Zaak D, Hofstetter A, Frimberger D, Schneede P. Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd: YAG laser treatment. Urology. 2003;61:1011–5. [CrossRef]
- 70. Blokker RS, Lock TM, de Boorder T. Comparing thulium laser and Nd: YAG laser in the treatment of genital and urethral condylomata acuminata in male patients. Lasers Surg Med. 2013;45:582–8. [CrossRef]
- 71. Gonzalvo Pérez V, Ramada Benlloch F, Blasco Alfonso JE, Donderis Guastavino C, Pallas Costa Y, Navalón Verdejo P, Orts JZ. Electrofulguración endoscópica de los condilomas acuminados intrauretrales [Endoscopic electrofulguration of intraurethral condylomata acuminata]. Actas Urol Esp. 1994;18:234–6. https:// pubmed.ncbi.nlm.nih.gov/8036954/
- 72. Tuğlu D. The use of laser in urologic surgery. Turk Urol Sem. 2011;2:134–9. [CrossRef]
- 73. Aynaud O, Casanova JM, Barrasso R. Nouvelles techniques ambulatoires de détection et de traitements des condylomes urétraux chez l’homme. A propos de 2 cas [New ambulatory techniques for the detection and treatment of urethral condyloma in men. Apropos of 2 cases]. J Urol (Paris). 1991;97:29–32. https:// pubmed.ncbi.nlm.nih.gov/1849944/
- 74. Ge CG, Jiang J, Jiang Q, Liu C, Hu ZL, Liang PH, Zhang W-L. Holmium: YAG laser ablation combined intraurethral fluorouracil perfusion as treatment option for intraurethral Condyloma acuminata in men. Minerva Urol Nefrol. 2014;66:77–81. https:// pubmed.ncbi.nlm.nih.gov/24721943/
- 75. Smith JA Jr. Laser treatment of the urethra and prostate. Semin Urol. 1991;9:180–4. https://pubmed.ncbi.nlm.nih.gov/1719597/
- 76. Timm B, Connor T, Liodakis P, Jayarajan J. Pan-urethral condylomata acuminata –a primary treatment recommendation based on our experience. Urol Case Rep. 2020;31:101149. [CrossRef]
- 77. Wen YC, Wu HH, Chen KK. Pan-urethral wart treated with 5-fluorouracil intraurethral instillation. J Chin Med Assoc. 2006;69:391–2. [CrossRef]
- 78. Dretler SP, Klein LA. The eradication of intraurethral condyloma acuminata with 5 per cent 5-fluorouracil cream. J Urol. 1975;113:195–8. [CrossRef]
- 79. Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. Human papillomaviruses in urological malignancies: a critical assessment. Urol Oncol. 2014;32:46.e19–27. [CrossRef]
- 80. Cai T, Di Vico T, Durante J, Tognarelli A, Bartoletti R. Human papilloma virus and genitourinary cancers: a narrative review. Minerva Urol Nefrol. 2018;70:579–87. [CrossRef]
- 81. Marchionne E, Perez C, Hui A, Khachemoune A. Penile squamous cell carcinoma: a review of the literature and case report treated with Mohs micrographic surgery. An Bras Dermatol. 2017;92:95– 9. [CrossRef]
- 82. Adami HO, Kuper H, Andersson SO, Bergström R, Dillner J. Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2003;12:872–5. https://pubmed. ncbi.nlm.nih.gov/14504197/
- 83. Singh N, Hussain S, Kakkar N, Singh SK, Sobti RC, Bharadwaj M. Implication of high risk human papillomavirus HR-HPV infection in prostate cancer in Indian population --a pioneering case-control analysis. Sci Rep. 2015;5:7822. [CrossRef]
- 84. Lawson JS, Glenn WK. Multiple pathogens and prostate cancer. Infect Agent Cancer. 2022;17:23. [CrossRef]
- 85. Moghoofei M, Keshavarz M, Ghorbani S, Babaei F, Nahand JS, Tavakoli A, et al. Association between human papillomavirus infection and prostate cancer: A global systematic review and metaanalysis. Asia Pac J Clin Oncol. 2019;15:e59–67. [CrossRef]
- 86. Sutcliffe S, Viscidi RP, Till C, Goodman PJ, Hoque AM, Hsing AW, et al. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2010;19:614–8. [CrossRef]
- 87. Maloney KE, Weiner JS, Walther PJ. Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: Evaluation by differential polymerase chain reaction. J Urol. 1994;154:360. [CrossRef]
- 88. LaRue H, Simoneau M, Fradet Y. Human papillomavirus in transitional cell carcinoma of the urinary bladder. Clin Cancer Res. 1995;1:4. https://pubmed.ncbi.nlm.nih.gov/9816001/
- 89. Jørgensen KR, Jensen JB. Human papillomavirus and urinary bladder cancer revisited. APMIS. 2020;128:72–9. [CrossRef]
- 90. Khatami A, Salavatiha Z, Razizadeh MH. Bladder cancer and human papillomavirus association: a systematic review and metaanalysis. Infect Agent Cancer. 2022;17:3. [CrossRef]
- 91. Gutiérrez J, Jiménez A, de Dios Luna J, Soto MJ, Sorlózano A. Meta-analysis of studies analyzing the relationship between bladder cancer and infection by human papillomavirus. J Urol. 2006;176(6 Pt 1):2474–81; discussion 2481. [CrossRef]
- 92. Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis. 2011;204:217–23. [CrossRef]
- 93. Muresu N, Di Lorenzo B, Saderi L, Sechi I, Del Rio A, Piana A, et al. Prevalence of human papilloma virus infection in bladder cancer: a systematic review. Diagnostics (Basel). 2022;12:1759. [CrossRef]
- 94. Muscianisi F, De Toni L, Giorato G, Carosso A, Foresta C, Garolla A. Is HPV the novel target in male idiopathic infertility? A systematic review of the literature. Front Endocrinol (Lausanne). 2021;12:643539. [CrossRef]
- 95. Foresta C, Garolla A, Zuccarello D, Pizzol D, Moretti A, Barzon L, et al. Human papillomavirus found in sperm head of young adult males affects the progressive motility. Fertil Steril. 2010;93:802–6. [CrossRef]
- 96. De Toni L, Cosci I, Carosso A, Barzon L, Engl B, Foresta C, et al. Hyaluronidase-based swim-up for semen selection in patients with human papillomavirus semen infection. Biol Reprod. 2021;104:211–22. [CrossRef]
- 97. Weinberg M, Sar-Shalom Nahshon C, Feferkorn I, Bornstein J. Evaluation of human papilloma virus in semen as a risk factor for low sperm quality and poor in vitro fertilization outcomes: a systematic review and meta-analysis. Fertil Steril. 2020;113:955– 69.e4. [CrossRef]
- 98. Laprise C, Trottier H, Monnier P, Coutlée F, Mayrand MH. Prevalence of human papillomaviruses in semen: a systematic review and meta-analysis. Hum Reprod. 2014;29:640–51. [CrossRef]
- 99. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe. 2010;8:260–70. [CrossRef ]
- 100. Mariz FC, Bender N, Anantharaman D, Basu P, Bhatla N, Pillai MR, et al. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 2020;5:14. [CrossRef]
- 101. Winer RL, Hughes JP, Feng Q, Stern JE, Xi LF, Koutsky LA. Incident detection of high-risk human papillomavirus infections in a cohort of high-risk women aged 25-65 years. J Infect Dis. 2016;214:665–75. [CrossRef]
- 102. Cyrus N, Blechman AB, Leboeuf M, Belyaeva EA, de Koning MN, Quint KD, et al. Effect of quadrivalent human papillomavirus vaccination on oral squamous cell papillomas. JAMA Dermatol. 2015;151:1359–63. [CrossRef]
- 103. Kreuter A, Waterboer T, Wieland U. Regression of cutaneous warts in a patient with WILD syndrome following recombinant quadrivalent human papillomavirus vaccination. Arch Dermatol. 2010;146:1196–7. [CrossRef]
- 104. Gilson R, Nugent D, Bennett K, Doré CJ, Murray ML, Meadows J, et al. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. Health Technol Assess. 2020;24:1–86. [CrossRef]
- 105. Yang MY, Son JH, Kim GW, Kim HS, Ko HC, Kim MB, et al. Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients. J Dermatolog Treat. 2019;30:405–9. [CrossRef]
- 106. Thappa DM, Chiramel MJ. Evolving role of immunotherapy in the treatment of refractory warts. Indian Dermatol Online J. 2016;7:364–70. [CrossRef]
- 107. Madeleine MM, Johnson LG, Doody DR, Tipton ER, Carter JJ, Galloway DA. Natural antibodies to human papillomavirus 16 and recurrence of vulvar high-grade intraepithelial neoplasia (VIN3). J Low Genit Tract Dis. 2016;20:257–60. [CrossRef]
- 108. Neumann K, Cavalar M, Rody A, Friemert L, Beyer DA. Is surgical plume developing during routine LEEPs contaminated with high-risk HPV? A pilot series of experiments Arch Gynecol Obstet 2018;297:421–4. [CrossRef]
- 109. Morris BJ, Hankins CA. Effect of male circumcision on risk of sexually transmitted infections and cervical cancer in women. Lancet Glob Health. 2017;5:e1054–5. [CrossRef]
- 110. Larke N. Male circumcision, HIV and sexually transmitted infections: a review. Br J Nurs. 2010;19:629–34. [CrossRef]
- 111. Tobian AA, Gray RH, Quinn TC. Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med. 2010;164:78–84. [CrossRef]
- 112. Larke N, Thomas SL, Dos Santos Silva I, Weiss HA. Male circumcision and human papillomavirus infection in men: a systematic review and meta-analysis. J Infect Dis. 2011;204:1375– 90. [CrossRef]
- 113. Van Howe RS. Human papillomavirus and circumcision: a metaanalysis. J Infect. 2007;54:490–6. [CrossRef]
- 114. Albero G, Castellsagué X, Giuliano AR, Bosch FX. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis. 2012;39:104–13. [CrossRef]
- 115. Zhu YP, Jia ZW, Dai B, Ye DW, Kong YY, Chang K, et al. Relationship between circumcision and human papillomavirus infection: a systematic review and meta-analysis. Asian J Androl. 2017;19:125–31.
- 116. Smith JS, Backes DM, Hudgens MG, Mei W, Chakraborty H, Rohner E, et al. Male circumcision reduces penile HPV incidence and persistence: a randomized controlled trial in Kenya. Cancer Epidemiol Biomarkers Prev. 2021;30:1139–48. [CrossRef]
- 117. Shapiro SB, Wissing MD, Khosrow-Khavar F, El-Zein M, Burchell AN, Tellier PP, et al. Male circumcision and genital human papillomavirus (HPV) infection in males and their female sexual partners: findings from the HPV infection and transmission among couples through heterosexual activity (HITCH) cohort study. J Infect Dis. 2022;226:1184–94. [CrossRef]
- 118. Yuan T, Fitzpatrick T, Ko NY, Cai Y, Chen Y, Zhao J, et al. Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data. Lancet Glob Health. 2019;7:e436–7. [CrossRef]
- 119. Hebnes JB, Munk C, Frederiksen K, Joergensen HO, Iftner T, Kjaer SK. The role of circumcision, tobacco, and alcohol use in genital human papillomavirus infection among men from Denmark. Int J STD AIDS. 2021;32:1028–35. [CrossRef]
- 120. Eufrásio P, Jorge Pereira B, Graça B, Palmas A, Santiago F, Borges R, et al. Recomendações em HPV Masculino da Sociedade Portuguesa de Andrologia, Medicina Sexual e Reprodução: Prevenção [Recommendations in Male HPV from the Portuguese Society of Andrology, Sexual Medicine and Reproduction: Prevention]. Rev Int Androl. 2021;19:187–94. [CrossRef]
- 121. Fenwick SE, Botfield JR, Kidman P, McGeechan K, Bateson D. Views and experiences of the female condom in Australia: An exploratory cross-sectional survey of cisgender women. PLoS One. 2021;16:e0246664. [CrossRef]
- 122. Gutierrez D, Tan A, Strome A, Pomeranz MK. Dental dams in dermatology: An underutilized barrier method of protection. Int J Womens Dermatol. 2022;8:e008. [CrossRef]
- 123. Innerhofer V, Kofler B, Riechelmann H. High-Risk-HPV-Infektionen im Kopf-Hals-Bereich - Welche Bedeutung hat das Sexualverhalten? [Sexual behavior and high-risk HPV infection in the head and neck]. Laryngorhinootologie. 2020;99:647–57. [CrossRef]
- 124. Osterberg EC, Gaither TW, Awad MA, Truesdale MD, Allen I, Sutcliffe S, et al. Correlation between pubic hair grooming and STIs: results from a nationally representative probability sample. Sex Transm Infect. 2017;93:162–6. [CrossRef]
- 125. Kaderli R, Schnuriger B, Brugger LE. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis. 2014;29:899–908. [CrossRef]
- 126. Jensen SE, Lehman B, Antoni MH, Pereira DB. Virally mediated cervical cancer in the iatrogenically immunocompromised: applications for psychoneuroimmunology. Brain Behav Immun. 2007;21:758–66. [CrossRef]